-
ODTX share price: currently unavailable. Sorry, we currently don't have enough data to create an insight.
-
Price change
The price of ODTX shares has decreased $0.91 since the market last closed. This is a 5.08% drop.
-
Closed at $17.01.
The stock has remained unchanged in after-hours trading.
Key terms
About ODTX
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company which develops medicines for autoimmune and inflammatory diseases. Its programs include OD-001, an oral small-molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, and OD-002, an oral small-molecule inhibitor of solute carrier family 15 member 4, or SLC15A4. The company was founded by Gary D. Glick, Melissa Merrick and David L. Pompliano in April 2021 and is headquartered in Boston, MA.
-
Market cap: $802.43M
A market capitalization between $300 million and $2 billion places ODTX in the small capitalization category.
Key terms
Smart score
Latest ODTX news
ODTX Financials
-
ODTX total_revenue: currently unavailable. Sorry, we currently don't have enough data to create an insight.
-
ODTX net income: currently unavailable. Sorry, we currently don't have enough data to create an insight.
-
ODTX earnings per share: currently unavailable. Sorry, we currently don't have enough data to create an insight.
Key terms
ODTX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ODTX Competitors
-
How competitors are chosen
ODTX's competitors are included in the Health Technology sector and Biotechnology group
-
Market cap: $802.43M
A market capitalization between $300 million and $2 billion places ODTX in the small capitalization category.
